Literature DB >> 21474589

Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.

Julia M Hofstra1, Laurence H Beck, David M Beck, Jack F Wetzels, David J Salant.   

Abstract

BACKGROUND AND OBJECTIVES: Circulating autoantibodies against the M-type phospholipase A(2) receptor (anti-PLA(2)R) were recently identified in the majority of patients in the United States with idiopathic membranous nephropathy (iMN). The objectives of this study were to assess the prevalence of anti-PLA(2)R in a separate, European cohort of iMN patients and to correlate the presence of anti-PLA(2)R with clinical parameters reflective of disease activity. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Anti-PLA(2)R levels were blindly assessed by a Western blot immunoassay in 54 serum samples from 18 patients with iMN collected in various stages of clinical disease. Anti-PLA(2)R levels were correlated with other clinical parameters.
RESULTS: 77.8% of iMN patients in our cohort had antibodies reactive with human PLA(2)R. The antibody levels in these patients correlated strongly with both clinical status and proteinuria (r = 0.73, P < 0.01).
CONCLUSIONS: The role of PLA(2)R as a major antigen in iMN was confirmed in an independent, European patient cohort, and levels of circulating anti-PLA(2)R revealed a strong correlation with clinical disease activity. We propose that detection and measurement of these autoantibodies may provide a tool for monitoring of disease activity and treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21474589      PMCID: PMC3109923          DOI: 10.2215/CJN.07210810

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  9 in total

1.  Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis.

Authors:  B J Van Damme; G J Fleuren; W W Bakker; R L Vernier; P J Hoedemaeker
Journal:  Lab Invest       Date:  1978-04       Impact factor: 5.662

2.  PLA2R autoantibodies and recurrent membranous nephropathy after transplantation.

Authors:  Rolf Stahl; Elion Hoxha; Kai Fechner
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

Review 3.  Membranous nephropathy: recent travels and new roads ahead.

Authors:  Laurence H Beck; David J Salant
Journal:  Kidney Int       Date:  2010-02-24       Impact factor: 10.612

4.  Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study.

Authors:  Amanda J W Branten; Peggy W du Buf-Vereijken; Ina S Klasen; Frank H Bosch; Geert W Feith; Daan A Hollander; Jack F Wetzels
Journal:  J Am Soc Nephrol       Date:  2004-11-24       Impact factor: 10.121

5.  Autoimmunity in membranous nephropathy targets aldose reductase and SOD2.

Authors:  Marco Prunotto; Maria Luisa Carnevali; Giovanni Candiano; Corrado Murtas; Maurizio Bruschi; Emilia Corradini; Antonella Trivelli; Alberto Magnasco; Andrea Petretto; Laura Santucci; Silvia Mattei; Rita Gatti; Francesco Scolari; Peter Kador; Landino Allegri; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2010-02-11       Impact factor: 10.121

6.  Experimental glomerulonephritis in the isolated perfused rat kidney.

Authors:  W G Couser; D R Steinmuller; M M Stilmant; D J Salant; L M Lowenstein
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

7.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

8.  Fetomaternal alloimmunization with antenatal glomerulopathies.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  Ann N Y Acad Sci       Date:  2007-09       Impact factor: 5.691

9.  Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions.

Authors:  W HEYMANN; D B HACKEL; S HARWOOD; S G WILSON; J L HUNTER
Journal:  Proc Soc Exp Biol Med       Date:  1959-04
  9 in total
  147 in total

1.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.

Authors:  Nicola M Tomas; Laurence H Beck; Catherine Meyer-Schwesinger; Barbara Seitz-Polski; Hong Ma; Gunther Zahner; Guillaume Dolla; Elion Hoxha; Udo Helmchen; Anne-Sophie Dabert-Gay; Delphine Debayle; Michael Merchant; Jon Klein; David J Salant; Rolf A K Stahl; Gérard Lambeau
Journal:  N Engl J Med       Date:  2014-11-13       Impact factor: 91.245

2.  Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy.

Authors:  Jan A J G van den Brand; Julia M Hofstra; Jack F M Wetzels
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 8.237

3.  Nephrotic syndrome: A new specific test for idiopathic membranous nephropathy.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  Nat Rev Nephrol       Date:  2011-08-09       Impact factor: 28.314

4.  M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.

Authors:  Elion Hoxha; Sigrid Harendza; Hans Pinnschmidt; Ulf Panzer; Rolf A K Stahl
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-29       Impact factor: 8.237

5.  Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy.

Authors:  Marieke J H Coenen; Julia M Hofstra; Hanna Debiec; Horia C Stanescu; Alan J Medlar; Bénédicte Stengel; Anne Boland-Augé; Johanne M Groothuismink; Detlef Bockenhauer; Steve H Powis; Peter W Mathieson; Paul E Brenchley; Robert Kleta; Jack F M Wetzels; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

6.  Long-term outcomes of initial therapy for idiopathic membranous nephropathy.

Authors:  Masayo Sato; Takashi Takei; Takahito Moriyama; Mitsuyo Itabashi; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2016-12-20       Impact factor: 2.801

7.  The Most N-Terminal Region of THSD7A Is the Predominant Target for Autoimmunity in THSD7A-Associated Membranous Nephropathy.

Authors:  Larissa Seifert; Elion Hoxha; Anna M Eichhoff; Gunther Zahner; Silke Dehde; Linda Reinhard; Friedrich Koch-Nolte; Rolf A K Stahl; Nicola M Tomas
Journal:  J Am Soc Nephrol       Date:  2018-03-19       Impact factor: 10.121

8.  Anti-phospholipase A₂ receptor antibodies in recurrent membranous nephropathy.

Authors:  A Kattah; R Ayalon; L H Beck; S Sethi; D G Sandor; F G Cosio; M J Gandhi; E C Lorenz; D J Salant; F C Fervenza
Journal:  Am J Transplant       Date:  2015-03-12       Impact factor: 8.086

9.  Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese.

Authors:  Norifumi Hayashi; Shin'ichi Akiyama; Hiroshi Okuyama; Yuki Matsui; Hiroki Adachi; Hideki Yamaya; Shoichi Maruyama; Enyu Imai; Seiichi Matsuo; Hitoshi Yokoyama
Journal:  Clin Exp Nephrol       Date:  2014-12-10       Impact factor: 2.801

10.  Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.

Authors:  Rossana Malatesta-Muncher; Karen W Eldin; Laurence H Beck; Mini Michael
Journal:  Pediatr Nephrol       Date:  2018-03-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.